Similar results were observed in the activating KRAS-mutant colon cancer cell line HCT116, where braftide reduced the CDC37–RAF interaction at lower doses than in HEK293 cells, suggesting this effect is not cell line specific (Fig. S1, A–E). Here, KRAS is linked to malignant colon neoplasm.